Grant: Catalyst Grant: Pilot Projects in Aging
Université Laval
$50,000.00
Senescence acceleration in the 3xTg-AD model of Alzheimer's disease
EF 2008-09
Résumé
Aging is critical to AD. Even for people who have strong genetic risk, the disease usually develops after 60. To reproduce the neuropathology of Alzheimer's disease (AD), a wide number of transgenic mice have been produced and characterized in the last decades. However, these models do not fully replicate the death of brain cells and the neurodegeneration that occurs in the disease. A simple reason is perhaps that mice do not live long enough. Indeed, a mouse in a clean laboratory setting lives for 2 years at best. In contrast, 90% of patients suffering from AD in the US are 75 years and older.
Since it is not possible to extensively prolong the lifespan of a mouse, we propose to develop a strategy to speed up the aging process in transgenic mice in the hope of generating more extensive plaques and tangles and, ultimately, death of brain cells. To that aim, we will cross AD transgenic mice with another type of mice known to age much faster than ordinary mice. The AD transgenic mouse that we will use is called "3xTg-AD" because they develop both plaques and tangles in their brain. The 3xTg-AD mouse is one of the closest to AD because it display memory deficits and the widest range of brain marker of AD. The fast aging mice that we are proposing to use are called "senescence-accelerated mouse" or SAM and they age at least twice as fast as control mice.
If our hypothesis is correct, acceleration the aging in 3xTg-AD/SAM offsprings will lead to an animal model closer to AD.
This will be extremely helpful to: (1) better understand why aging factors play such an important role in AD, (2) have a brand new model of AD to investigate innovative drug treatments.
Programme
Catalyst Grant: Pilot Projects in Aging
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
179428
Name
Calon Frédéric
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Institute of Aging Pilot Projects
Projecttitle
Senescence acceleration in the 3xTg-AD model of Alzheimer's disease
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Pilot Projects in Aging
Keyworddelim
3xtg-Ad Mice; Aging; Alzheimer; Neuropathology; Sam Mice; Senescence
Abstract
Aging is critical to AD. Even for people who have strong genetic risk, the disease usually develops after 60. To reproduce the neuropathology of Alzheimer's disease (AD), a wide number of transgenic mice have been produced and characterized in the last decades. However, these models do not fully replicate the death of brain cells and the neurodegeneration that occurs in the disease. A simple reason is perhaps that mice do not live long enough. Indeed, a mouse in a clean laboratory setting lives for 2 years at best. In contrast, 90% of patients suffering from AD in the US are 75 years and older.
Since it is not possible to extensively prolong the lifespan of a mouse, we propose to develop a strategy to speed up the aging process in transgenic mice in the hope of generating more extensive plaques and tangles and, ultimately, death of brain cells. To that aim, we will cross AD transgenic mice with another type of mice known to age much faster than ordinary mice. The AD transgenic mouse that we will use is called "3xTg-AD" because they develop both plaques and tangles in their brain. The 3xTg-AD mouse is one of the closest to AD because it display memory deficits and the widest range of brain marker of AD. The fast aging mice that we are proposing to use are called "senescence-accelerated mouse" or SAM and they age at least twice as fast as control mice.
If our hypothesis is correct, acceleration the aging in 3xTg-AD/SAM offsprings will lead to an animal model closer to AD.
This will be extremely helpful to: (1) better understand why aging factors play such an important role in AD, (2) have a brand new model of AD to investigate innovative drug treatments.
Competitiondate
200903
Approvedterm2
1 yr 0 mth
Pinamesdelim
Calon, Frédéric
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $50,000~ $0~